Journal of VitreoRetinal Diseases最新文献

{"title":"Clinical Features and Optical Coherence Tomography Angiography in Neovascular Age-Related Macular Degeneration and Pachychoroid Neovasculopathy.","authors":"Angsita Khaohoen, Yodpong Chantarasorn","doi":"10.1177/24741264251359847","DOIUrl":"10.1177/24741264251359847","url":null,"abstract":"<p><p><b>Purpose:</b> To investigate differences in baseline characteristics, outcomes, and metrics of swept-source optical coherence tomography (SS-OCT) angiography between drusen-associated neovascular age-related macular degeneration (nAMD) vs pachychoroid neovasculopathy. <b>Methods:</b> This prospective cohort study enrolled 1 eye per patient with treatment-naïve nAMD or pachychoroid neovasculopathy who underwent 3 monthly bevacizumab injections followed by a treat-and-extend regimen for 12 months or longer. Eligible patients were classified into 2 groups: those with drusen-associated nAMD and those with pachychoroid neovasculopathy. Drusen-associated nAMD refers to macular neovascularization (MNV) or polypoidal lesions surrounded by subretinal drusenoid deposits or soft drusen 63 μm or larger in diameter. The outcomes were collected at baseline, 6 months, and 12 months. <b>Results:</b> Patients with drusen-bordering MNV (51 cases) were older (69.6 years vs 64.2 years) and had a smaller ratio of low-density to high-density lipoprotein cholesterol (1.85 vs 2.14), longer daily sleep hours (7.03 hours vs 6.07 hours), a smaller proportion of patients with a history of central serous chorioretinopathy (CSCR) (0% vs 12.5%), and smaller baseline central choroidal volume compared with those with pachychoroid neovasculopathy (57 cases). At 12 months, eyes with drusen exhibited a lower choroidal vascularity index, larger foveal thickness (327 µm vs 273 µm), and more antivascular endothelial growth factor injections per year (7.0 vs 5.2) compared with eyes with pachychoroid neovasculopathy. Regarding secondary outcomes, a closed-circuit vascular pattern was associated with persistent retinal fluid at study completion. <b>Conclusions:</b> Patients with pachychoroid neovasculopathy appear to carry some systemic risk factors for CSCR, whereas patients with drusen-related nAMD had inferior responses to bevacizumab monotherapy and greater choriocapillaris hypoperfusion (characterized by thinner choroidal volume and lower choroidal vascularity index values).</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251359847"},"PeriodicalIF":0.8,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12354402/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-Effectiveness of Treatments for Diabetic Macular Edema: Simulated Bevacizumab-First Step Therapy Versus Real-World Practice.","authors":"Ella H Leung, Dilraj S Grewal, Emanuel Gerbi, Miguel Busquets, Philip Niles, Dan A Gong, Anton M Kolomeyer, Nitika Aggarwal, Nick Boucher, Jill Blim, Reginald Sanders, Paul Hahn","doi":"10.1177/24741264251359888","DOIUrl":"10.1177/24741264251359888","url":null,"abstract":"<p><p><b>Purpose:</b> To compare the incremental cost-effectiveness of a clinical trial-simulated step-therapy versus real-world treatment for diabetic macular edema (DME). <b>Methods:</b> A theoretical Markov model (follow-up of 2 years and lifetime of 17 years) from the 2025 US societal perspective was used to compare the costs and cost-effectiveness between bevacizumab-first (Protocol AC) and real-world regimens from the Vestrum Health database. The modeling used mean characteristics from a reference case and analyzed low- and high-cost scenarios, total societal costs from formal and informal healthcare and non-healthcare sectors, and differences in utility (visual acuity outcomes) between arms. <b>Results:</b> Protocol AC bevacizumab-first in the reference case was 14% more expensive at 2 years, with a total adjusted societal cost of $69 850 versus $61 304 for real-world treatment. Although visual acuity gains were higher with Protocol AC, the incremental cost-utility ratio (ICUR) was $105 335/quality-adjusted life years (QALY) at 2 years and $151 032/QALY over 17 years, higher than most societal willingness-to-pay thresholds. In the low-cost scenario, Protocol AC was neither cost-saving nor cost-effective at 2 years (ICUR $82 283/QALY) but was cost-effective over 17 years (ICUR $591/QALY). In the high-cost scenario, Protocol AC was not cost-effective at 2 years (ICUR $219 420/QALY) or 17 years (ICUR $207 589/QALY). Probability sensitivity analysis showed that Protocol AC was more expensive in 87% of modeled scenarios and not cost-effective in 76%. <b>Conclusions:</b> Compared with real-world treatment, protocol AC bevacizumab-first treatment for DME was generally not cost-saving. Although better vision outcomes were achieved with bevacizumab-first, the protocol was generally not cost-effective due to greater treatment burdens.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251359888"},"PeriodicalIF":0.8,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339501/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144847308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal Trends and Regional Variations in Retinal Detachment Repair Procedures in the United States.","authors":"Fateme Montazeri, Parisa Emami-Naeini","doi":"10.1177/24741264251358073","DOIUrl":"10.1177/24741264251358073","url":null,"abstract":"<p><p><b>Purpose:</b>To describe whether monitoring shifts in practice patterns and reimbursements for retinal detachment (RD), a sight-threatening condition requiring prompt treatment, can improve patient outcomes and optimize healthcare resource allocation. <b>Methods:</b> This cross-sectional population-based study evaluated trends and geographic variations in RD repair procedures using Medicare fee-for-service provider utilization and payment Part B data from 2013 to 2021. Our analysis used Current Procedural Terminology codes for pars plana vitrectomy (PPV), complex repair, scleral buckling, pneumatic retinopexy, photocoagulation, and cryotherapy. We also included an examination of changes in insurance reimbursement. <b>Results:</b> Between 2013 and 2019, we observed a significant, 7.3% increase in the total number of procedures. However, in 2020, the COVID-19 pandemic led to an 11.1% decline in procedures, with an incomplete recovery in 2021. While use of other procedures declined, PPV and complex repair were the most common across geographic regions, showing rising trends over time. The average Medicare reimbursement for RD repairs dropped by 29%, with cryotherapy facing the largest reduction. Female ophthalmologists received significantly lower average standardized Medicare reimbursements for PPV (adjusted mean difference, $81.90; 95% CI, 48-115.80; <i>P <</i> .001) and complex repair (adjusted mean difference, $218.30; 95% CI, 156-280.70; <i>P</i> < .001) and higher reimbursements for pneumatic retinopexy procedures (adjusted mean difference, $13.80; 95% CI, 3.50-24.20; <i>P =</i> .009) after adjusting for confounders. <b>Conclusions:</b> PPV has become the predominant procedure among Medicare beneficiaries across geographic regions. Decreasing reimbursements, the COVID-19 pandemic, and patient- and surgeon-related factors influence these trends in RD repair. Significant reimbursement disparities between male and female ophthalmologists for pneumatic retinopexy, PPV, and complex repair procedures have also been identified.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251358073"},"PeriodicalIF":0.8,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339484/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144847267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intraocular Inflammation Following Intravitreal Faricimab: Insights from Five Bilateral Cases.","authors":"Niku Dhillon, Shona Macleod","doi":"10.1177/24741264251358623","DOIUrl":"10.1177/24741264251358623","url":null,"abstract":"<p><p><b>Purpose:</b> To evaluate the incidence of intraocular inflammation (IOI) after intravitreal (IVT) faricimab injection. <b>Methods:</b> A retrospective observational study was performed of all patients who received IVT faricimab injections at NHS Highland between January 2023 and June 2024 and subsequently developed IOI. <b>Results:</b> IOI was seen in 11 eyes of 6 patients after faricimab injection. All aqueous and vitreous cultures were negative. Among patients who received bilateral faricimab injections, the incidence of IOI was 8.5% (5/59). Four eyes experienced a vision loss of 11.5 ± 8.6 Early Treatment Diabetic Retinopathy Study letters. Cases were characterized by a delayed onset of subacute symptoms after injection, keratic precipitates, and elevated intraocular pressure. <b>Conclusions:</b> Although the overall incidence of faricimab-related IOI is low, our findings highlight the need for increased vigilance in patients receiving bilateral faricimab injections.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251358623"},"PeriodicalIF":0.8,"publicationDate":"2025-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12336167/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144835466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations between Electronic Cigarettes, Smokeless Tobacco, and Age-related Macular Degeneration in the 2017 United States National Health Interview Survey.","authors":"Alejandro Ochoa, Jessica Brinson, Katrina Chin Loy, Salman J Yousuf","doi":"10.1177/24741264251362886","DOIUrl":"10.1177/24741264251362886","url":null,"abstract":"<p><p><b>Purpose:</b> To investigate the association of cigarette-alternative tobacco products with age-related macular degeneration (AMD). <b>Methods</b>: The 2017 National Health Interview Survey, comprising epidemiologic data from a nationally representative sample of the US adult population, was queried to identify all participants who reported using electronic cigarettes (e-cigarettes) and smokeless tobacco and whether or not they had AMD. Participant characteristics were analyzed and a multivariable regression was performed to determine predictors of AMD, adjusting for age, sex, race/ethnicity, number of packs of cigarettes smoked per day, and body mass index. <b>Results</b>: The final analytic sample included 26 689 survey respondents, representing the US national population of 246 242 859 adults. The weighted prevalence of AMD was 1.9% (95% confidence interval [95% CI], 1.8-2.1%). Compared to those without AMD, adults with AMD were significantly older, more often female, and disproportionately non-Hispanic White (<i>P</i> < .0001). In adjusted models (including adjustment for number of packs of cigarettes smoked per day), the odds ratios for developing AMD were 1.49 (95% CI, 1.02 to 2.18) in adults who used smokeless tobacco products and 1.08 (95% CI, 0.73 to 1.60) in adults who used e-cigarettes, compared to those who had never used these products. <b>Conclusions</b>: This study identified smokeless tobacco use as a novel factor associated with AMD among a nationally representative sample, suggesting its avoidance may reduce the risk of developing AMD. Additional studies are needed to better understand the long-term effects of e-cigarettes on AMD.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251362886"},"PeriodicalIF":0.8,"publicationDate":"2025-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12336162/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144835434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Performance of Novel Single-Use Lenses in Vitreoretinal Surgery.","authors":"Ivo De Clerck, Joachim Van Calster, Peter Stalmans","doi":"10.1177/24741264251359050","DOIUrl":"10.1177/24741264251359050","url":null,"abstract":"<p><p><b>Purpose:</b> To conduct a premarket study of 3 new single-use lenses for the RESIGHT ophthalmoscopy system during routine vitrectomy surgery. <b>Methods:</b> In this investigator-initiated prospective, academic, interventional case study from a single center, 3 new single-use lenses (a wide-angle lens, ultra wide-angle lens, and macula lens) were compared head-to-head with reusable lenses in 181 patients who had retinal detachment surgery (n = 89) or macular surgery (n = 92). After each surgery, participating surgeons completed a survey grading the performance of the new single-use lenses compared with the reusable lenses. <b>Results:</b> For all 3 single-use lenses in the RESIGHT system, condensation was significantly reduced compared with that of the reusable lenses, and the image quality was clearly better. The telescopic design of the ultrawide-angle lens allowed a better view of the retinal periphery, enabling complete shaving of the vitreous base without indentation in the majority of phacovitrectomy cases. The macula lens offered a wider field of view with similar image quality to that of a flat contact lens, allowing better visualization of the surgical instruments without sacrificing detail in the image, thus facilitating safer surgery. The improved resolution of the wide-angle lens allowed sufficient magnification for use in macular surgery. <b>Conclusions:</b> Compared with their reusable counterparts, the newly designed single-use lenses for the RESIGHT system offer significant improvements during routine vitrectomy surgery.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251359050"},"PeriodicalIF":0.8,"publicationDate":"2025-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12336160/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144835465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors for Macular Hole Development After Pars Plana Vitrectomy for Rhegmatogenous Retinal Detachment.","authors":"Yangyiran Xie, Rebecca Z Lin, Xiangyu Ji, John Fitzpatrick, Nathan D Foxworth, Qingxia Chen, Akshay S Thomas, Kisha D Piggott, Avni P Finn","doi":"10.1177/24741264251362891","DOIUrl":"10.1177/24741264251362891","url":null,"abstract":"<p><p><b>Purpose:</b> To identify intraoperative and postoperative risk factors for macular hole (MH) formation after prior pars plana vitrectomy (PPV) for rhegmatogenous retinal detachment (RRD) repair. <b>Methods:</b> This retrospective case-control study compared eyes that developed MH after PPV for RRD (cases) and those that underwent PPV for RRD without forming MH (controls). Cases were matched to controls using propensity scores based on demographic, preoperative, and RRD characteristics. <b>Results:</b> The study included 44 case eyes and 44 control eyes. Median time to MH formation was 6.3 months. MH repair was successful in 95.1% of eyes, with significant improvement in visual acuity (from 1.05 logMAR to 0.84 logMAR; <i>P</i> = .001). Use of perfluorocarbon usage was higher at the time of RRD repair in eyes that developed MH (16% vs 0%; <i>P</i> = .012). Post-PPV formation of an epiretinal membrane (ERM) prior to MH was higher in the case group (61% vs 43%; <i>P</i> = .057), as was post-PPV formation of cystoid macular edema (CME) prior to MH (75.9% vs 9.1%; <i>P</i> < 0.001). <b>Conclusions:</b> This case-control study found that eyes developing post-PPV CME are at highest risk for MH formation after surgery for RRD. The development of MH after PPV for RRD most commonly occurs several months after surgery. Mitigating the formation of ERM and treating postoperative CME are important to long-term visual prognosis after RRD repair.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251362891"},"PeriodicalIF":0.8,"publicationDate":"2025-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12336166/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144835467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical Outcomes of Primary Noncomplex Rhegmatogenous Retinal Detachment in 20- to 45-Year-Old Young Adults.","authors":"Michael J Ammar, Jessica J Lee, Louis Cai, Kristine Y Wang, Anthony Obeid, Claire Ryan, Omesh P Gupta, Jason Hsu, Nora J Forbes, Matthew R Starr, Luv G Patel, Taku Wakabayashi, Antonio Capone, Geoffrey G Emerson, Dean Eliott, Daniel P Joseph, Carl D Regillo, Edwin H Ryan, Yoshihiro Yonekawa","doi":"10.1177/24741264251359055","DOIUrl":"10.1177/24741264251359055","url":null,"abstract":"<p><p><b>Purpose:</b> To analyze anatomic and visual outcomes of young adults with uncomplicated primary rhegmatogenous retinal detachment (RRD) treated with scleral buckle, pars plana vitrectomy (PPV), or combined PPV and scleral buckle. <b>Methods:</b> Patients included in the Primary Retinal Detachment Outcomes study with a minimum of 6 months follow-up were evaluated in this multicenter interventional cohort study,. Patients with complex RRDs were excluded. Primary outcomes were single surgery anatomic success and final visual acuity (VA). <b>Results:</b> Scleral buckle was performed in 91 eyes (55%), PPV in 32 (19%), and combined PPV and scleral buckle in 42 (25%). Single surgery anatomic success rates were 79.3% for PPV alone, 83.7% for primary scleral buckle, and 92.7% for combined PPV and scleral buckle (analysis of variance, <i>P</i> = .25). When adjusting for potential risk factors, eyes that had PPV alone were more likely to redetach compared with those that had combined PPV and scleral buckle (hazard ratio [HR], 7.24, 95% CI, 1.25-42.1; <i>P</i> = .03), while rates of redetachment were similar in eyes that had scleral buckle alone and combined PPV and scleral buckle (HR, 3.24, 95% CI, 0.63-16.63; <i>P</i> = .16). However, eyes that had combined PPV and scleral buckle were less likely to result in good vision compared with eyes that had scleral buckle alone (odds ratio [OR], 0.26, 95% CI, 0.07-0.94; <i>P</i> = .04). Similarly, eyes that had PPV alone were less likely to obtain good vision compared with eyes that only had scleral buckle (OR, 0.20, 95% CI, 0.05-0.81; <i>P</i> = .02). <b>Conclusions:</b> For young adults in this study, the best visual outcomes resulted from scleral buckle, and a higher single surgery success rate was found with combined PPV and scleral buckle.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251359055"},"PeriodicalIF":0.8,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic Diabetic Tractional Retinal Detachment and Poor Visual Acuity: Should We Be Performing Surgery on These Patients?","authors":"Ryan B Rush, Sloan W Rush","doi":"10.1177/24741264251359851","DOIUrl":"10.1177/24741264251359851","url":null,"abstract":"<p><p><b>Purpose:</b> To evaluate the benefits of pars plana vitrectomy (PPV) in subjects with poor visual acuity (VA) and a chronic macula-involving tractional retinal detachment (TRD) secondary to proliferative diabetic retinopathy (PDR). <b>Methods:</b> A retrospective, case-controlled chart review was conducted, and patients were divided into (1) a study group that underwent PPV and (2) a control group in which PPV was declined. Both study and control subjects had a baseline VA of hand motions at 3 feet or worse, a PDR-associated macula-involving TRD for more than 6 months, and at least 12 months of follow-up. <b>Results:</b> A total of 175 subjects were analyzed. There were no differences in baseline characteristics between cohorts. The change in VA was improved by 0.78 logMAR (95% CI, 0.64-0.90) in the study group compared with 0.03 logMAR (95% CI, -0.15 to 0.22) in the control group (<i>P <</i> .0001). The rates of achieving 20/200 or better Snellen VA and 20/50 or better Snellen VA were increased in the study group compared with the control group (<i>P <</i> .0001 and <i>P =</i> .007, respectively), and the rates of becoming no light perception, developing neovascular glaucoma, or undergoing enucleation/evisceration during the study period were higher in the control group compared with the study group (<i>P</i> = .02, <i>P <</i> .0001, and <i>P</i> = .03, respectively). <b>Conclusions:</b> Patients with PDR with poor VA and a macula-involving TRD of more than 6 months duration still may have a more meaningful improvement in vision and fewer adverse events when PPV is performed than when PPV is declined in favor of less invasive options.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251359851"},"PeriodicalIF":0.8,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12328344/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and Optical Coherence Tomography Characteristics of Severe Intraretinal Silicone Oil Migration.","authors":"Carl Shen, Daisy Liu, Chao Chen, Sterling King, Mark Greve, David Ehmann, Mark Seamone","doi":"10.1177/24741264251356293","DOIUrl":"10.1177/24741264251356293","url":null,"abstract":"<p><p><b>Purpose:</b> To characterize the clinical and imaging features of patients presenting with a constellation of findings believed to represent severe intraretinal migration of silicone oil. <b>Methods:</b> Query of our institutional electronic medical record system for patients who underwent silicone oil removal. <b>Results:</b> Twenty-eight cases of severe IRSO were identified. All patients had characteristic round hypo-reflective spaces favoring the inner retinal layers on OCT with increased hyperreflectivity in the deeper retinal layers, and corresponding hyperreflective spherules on near-infrared enface imaging. All patients received 5000 centistoke silicone oil and had had their macular internal limiting membrane removed by the time of final silicone oil instillation. Oil was in situ for an average 220 ± 198 days before removal. Average follow up from time of oil out was 353 ± 529 days. <b>Conclusions:</b> We characterize an underrecognized phenotype of intraretinal silicone oil which presents with a constellation of OCT findings distinct from other consequences of silicone oil use.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251356293"},"PeriodicalIF":0.8,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12328352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}